Skip to content

Effectiveness of intralesional triamcinolone acetonide plus tacrolimus or tacrolimus alone in young patient with alopecia areata.

Comparison between intralesional triamcinolone acetonide plus tacrolimus and tacrolimus alone in young patient with alopecia areata

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250308064975N1
Enrollment
138
Registered
2025-05-20
Start date
2024-12-24
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia areata (AA) is an autoimmune disorder. Patient presenting with hairless baldness together with healthy skin and conserved follicular ostia. Hairs with exclamations mark and a test of positive pull are done to confrm diagnosis . Yellow spots can been seen on dermoscopy. Spared white hairs

Interventions

Intervention Groups Record 1:Group A (Intervention Group)

Sponsors

Shaheed mohtarma benazir bhutto medical university larkana
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patient age between 12-50 years of both genders. Patient diagnosed with alopecia areata.

Exclusion criteria

Exclusion criteria: Patient having SALT score < 50 at baseline Patient with autoimmune diseases Pregnant women Patient's on immunosuppression therapy. Non-consenting patient

Design outcomes

Primary

MeasureTime frame
Primary outcome in patients with alopecia areata after treatment with intralesional (I/L) triamcinolone and tacrolimus in a randomized clinical trial typically involves assessing hair regrowth. Using trichoscan that analyzes hair density, thickness, and regrowth and taking standardized photographs of the affected area at baseline and follow-up visits to visually assess hair regrowth.Hair regrowth scoring as SALT (Severity of Alopecia Tool) score. Timepoint: Patient is assessed ,before intervention and at 3,6,9,12 weeks after intervension. Method of measurement: Score based on SALT can be calculated using the measurement of the total percentage of hairs that are lost in four areas of the scalp — In the rightside profile (it accounts for 18% of the total area in the scalp), the left side profile (which also accounts for 18% of the total area in the scalp), at the vertex areas (40% of the total area of the scalp), and the posterior (24% of the total area of the scalp), as shown in the figure below. By including total percentage of hairs that are lost in each area are multiplied by the regions relative area, one attains a composite score total i.e the Score of SALT. The regrowth of the hair can be achieved through decreasing the SALT score (e.g, The SALT score can be consider 0 if there is complete hair regrowth. There is a simple tool for the calculation of SALT score based on loss of hair in each of the above mentioned areas.Online SALT score is available to predict hair regrow with treatment .

Secondary

MeasureTime frame
Side effects. Monitoring & documenting adverse effects related to the treatment ,skin irritation,bleeding ,scaring,telangiectasia. Timepoint: Patient will assessed at 3,6,9,12 weeks after intervension. Method of measurement: Patient self-report: patient will be asked to report any discomfort,such as skin irritation,dryness,or allergic reactions during follow up vists. Clinical observation:inspect the treated areas for signs of adverse reactions sach as redness ,swelling or peeling. Efficacy will be assesed using the same parameters as the intervension group: improvement in clinical signs, presence of initially soft hairs regrow followed by pigmented hairs.

Countries

Pakistan

Contacts

Public ContactDr Irfan shaikh

Shaheed mohtarma benazir bhutto medical university larkana

shaikhirfan913@gmail.com+92 71 5614111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026